Strategic Acquisition: Otsuka Pharmaceutical to Pay Up to $1.1 billion to Acquire Jnana Therapeutics' Drug Discovery Platform
Otsuka Pharmaceutical recently signed an agreement to acquire Jnana Therapeutics. According to the terms of the agreement, Otsuka Pharmaceutical will pay up to $800 million to the shareholders of Jnana upon completion of the acquisition, alongside an additional $325 million in development and regulatory milestones.
Otsuka Pharmaceutical's main motivation behind this deal is Jnana Therapeutics' drug discovery platform and pipeline led by a clinical-phase rare disease candidate, phenylketonuria (PKU). PKU is a rare genetic metabolic disorder in which phenylalanine accumulates to abnormally high levels in the blood. Focusing on this niche therapeutic area has given Jnana a competitive and unique edge.
Chemoproteomics is the study of determining how proteins interact with small molecules. Jnana's RAPID chemoproteomics platform is widely used in drug development and has proven to be highly effective for a range of malignancies alongside immune-mediated and neurological targets.
The RAPID platform leverages a high throughput, binding-based screening approach that is inherently flexible enabling the discovery of binding sites across the surface of a target protein and the identification of small molecules.
Related:
- Bruker Corp to buy Chemspeed in ramp-up of automation portfolio
- Exscientia and Amazon Web Services Join Forces to Maximise the Potential Of Generative AI in Drug Discovery
- Novo Nordisk Foundation and NVIDIA to Launch a State-of-the-Art National AI Research Centre
Initial public offering (IPO) is the process of offering shares of a private corporation to the public in new stock issuance for the first time. IPOs make it more difficult for drug discovery startups to take off so companies like Jnana are usually acquired by larger pharmaceutical manufacturers.
The acquisition of private biotechnology companies by large pharma is currently on the rise. For example, Jnana has also attracted interest from Roche who penned two partnerships with the US biotech including a $2 billion deal to contribute to discovery and preclinical work on multiple targets from cancer to immune-mediated diseases.
Acquisitions like this can offer a range of benefits to the pharmaceutical industry, combining expertise to help drive a drug through the development process. Given the difficult funding environment within the industry, this is crucial. The exchange of capital and ideas between big pharma and smaller drug companies continues to benefit drug development on a global scale.
Big pharma has the scale, resources, and de-risked technology to efficiently commercialise late-stage products and deliver them to the patient population quickly. Whereas smaller biotechnologies have a focused and flexible approach which enables fast-paced innovation in early stage of scientific translation. These small-scale companies are overwhelmingly responsible for driving drug innovation, accounting for 63% of all new prescription drug approvals.
